Le Lézard
Classified in: Health
Subjects: NPT, LEG, AVO

FRC's Patrina Mosley Testifies Before Senate Judiciary Committee on the 'Born Alive Abortion Survivors Protection Act'


WASHINGTON, Feb. 11, 2020 /PRNewswire/ -- Today, Family Research Council's Patrina Mosley, Director of Life, Culture, and Women's Advocacy, testified before the Senate Judiciary Committee on the Born-Alive Abortion Survivors Protection Act. She offered testimony on "The Infant Patient: Ensuring Appropriate Medical Care for Children Born Alive."

Family Research Council logo (PRNewsFoto/Family Research Council)

In her testimony, Mosley said, "In 2002, Congress did pass the Born-Alive Infants Protection Act... but a law is often only as good as its enforcement mechanisms." She said the Born-Alive Abortion Survivors Protection Act is needed because it would require "that practitioners must exercise professional skill, care, and diligence to preserve the life of infants who survive abortion... and legal penalties for abortionists who do not comply."

"So, the dreaded question becomes, what actually happens to a child born alive after a failed abortion attempt? Are they administered medical care or does infanticide take place, which is the act of killing of a newborn child?" continued Mosley.

Mosley cited CDC statistics which recorded at least 143 infants between 2003-2014 who died after an abortion procedure, without any federal prosecution because there is no federal statute to provide for one.

She also pointed out that 34 states have enacted additional protections for born alive abortion survivors, indicating that the federal law is not enough. However, only 15 states have the same strong protections that are reflected in the Born-Alive Abortion Survivors Protection Act.

Mosley reminded the committee of remarks made last year by Virginia Governor Ralph Northam, who suggested that a mother and doctor could have a "discussion" about whether or not a born-alive abortion survivor would survive.

"So, whether a newborn gets the chance to live or not is a matter for 'discussion,' while precious moments slip by as the infant is fighting for her life on the delivery table. At this point, we are no longer talking about abortion or a woman's body. We are talking about a child who has clearly become the patient," insisted Mosley.

Mosley concluded by refuting the claim that there are no born-alive abortion survivors by highlighting the stories of Gianna Jessen and Melissa Ohden, who survived abortions, and three babies who were born as early as 21-23 weeks and are "thriving today" because they were given care.

To read Mosley's full testimony, please click here

 

SOURCE Family Research Council


These press releases may also interest you

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....

at 10:00
Driving is the leading cause of work-related death each year in the United States, with nearly 40% of deaths on the job occurring on American roads according to the U.S. Bureau of Labor Statistics. A major contributing factor to road deaths each...

at 10:00
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according...



News published on and distributed by: